BioTalk Unzipped copertina

BioTalk Unzipped

BioTalk Unzipped

Di: Gregory Austin
Ascolta gratuitamente

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.
BioTalk Unzipped, hosted by Gregory Austin and Dr. Chad Briscoe, unzips the stories behind medical progress through candid, intelligent, and often entertaining conversations with leaders across biotechnology, pharmaceuticals, medical technology, clinical research, bioanalysis, and drug development. Each episode explores the science, strategy, setbacks, breakthroughs, and human stories shaping the future of medicine. From first-in-human trials and biomarkers to oncology, rare disease, AI, regulatory strategy, and emerging therapeutic technologies, BioTalk Unzipped makes complex life science topics engaging, accessible, and relevant. The show feels like the conversation you would want to overhear after a great scientific conference: thoughtful, unscripted, curious, and grounded in real-world experience. We bring listeners inside the decisions, discoveries, and personal journeys behind the therapies and technologies that may one day reduce suffering and improve lives.BioTalk Unzipped Disturbo fisico e malattia Economia Igiene e vita sana Scienza Scienze biologiche
Episodi
  • Is AI Changing Scientists? The Future of Pharma with Dr. Rob Dodge

    Is AI Changing Scientists? The Future of Pharma with Dr. Rob Dodge
    Oct 2 2026

    Rob Dodge says AI has made him an expert Python programmer, even though he never took a class in it. But does having new capabilities change what it means to be a scientist?

    Dr. Chad Briscoe sits down with Dr. Robert “Rob” Dodge at the AAPS National Biotechnology Conference in San Diego to discuss how artificial intelligence and machine learning are changing pharmaceutical research.

    Thank you to our sponsors

    TruTechnologies provides real-time clinical trial oversight, helping research teams improve protocol adherence and protect biospecimen integrity.

    https://trutechnologies.ai/

    Leucentra: Inspired by science, empowered by IT.

    https://leucentra.com/

    About the conversation

    Rob remembers when spreadsheets changed how scientists calculated and plotted their results. Today, AI helps him write code and investigate scientific data with less reliance on specialist programming support.

    He and Chad discuss where these tools are useful, where they fall short, and what scientists still need to bring to the work. Their conversation covers assay development, access to clinical data, scientific writing, and the challenges of using AI in regulated bioanalysis.

    Rob also shares his predictions for how machine learning could change established modeling approaches, including quantitative systems pharmacology and design of experiments.

    Throughout the discussion, he returns to a familiar principle: scientists still need to develop hypotheses, test them, and question their results.

    In this episode

    • How scientists are using AI to write Python programs
    • What advances in mass spectrometry mean for complex drug modalities
    • Machine learning for assay improvement and clinical data analysis
    • Why data quality and laboratory experience matter
    • Validation and quality assurance challenges in regulated research
    • Using AI to draft and review scientific documents
    • How independent consultants and smaller teams can use AI as a resource
    • Rob’s predictions for the next year in pharmaceutical science

    About Dr. Rob Dodge

    Robert “Rob” Dodge, PhD, is an independent bioanalytical consultant focused on artificial intelligence and machine learning in regulated bioanalysis.

    His more than 30 years in pharmaceutical science include biologics manufacturing, bioanalytical testing, and leadership roles at Bristol-Myers Squibb and Novartis. He co-founded Princeton Bio Lab and previously served as Director of Immunochemistry and Cell Biology at Pharmanet Development Group.

    Connect with Rob:

    https://www.linkedin.com/in/robert-dodge-phd/

    About BioTalk Unzipped

    Hosted by Gregory Austin and Dr. Chad Briscoe, BioTalk Unzipped uncovers the stories and science behind medical progress through conversations with scientists and leaders in biotechnology and drug development.

    Find more episodes:

    https://www.biotalkunzipped.com/

    Follow BioTalk Unzipped on your podcast app to hear new episodes as they’re released. If this conversation brings a colleague to mind, send it their way.
    Mostra di più Mostra meno
    36 min
  • Do Clinical Trials Take Too Much Blood? Patient-Centric Sampling with Joleen White

    Do Clinical Trials Take Too Much Blood? Patient-Centric Sampling with Joleen White
    Sep 11 2026
    Clinical trials often collect far more blood than an assay actually needs. Dr. Joleen White asks a more disciplined question: What information is required to make a sound decision, and how little sample can be collected without compromising that decision?In this episode of BioTalk Unzipped, recorded at the 2026 AAPS National Biotechnology Conference in San Diego, Dr. Chad Briscoe sits down with Joleen to explore patient-centric sampling, dried blood microsampling, global bioanalytical capacity, and the values behind better drug development.Joleen traces her path from a childhood friendship with someone living with cystic fibrosis to a career spanning BioMarin, BMS, Biogen, EMD Serono, the Gates Medical Research Institute, and BioData Solutions. She explains why bioanalysis became her way to help patients, why she eventually moved beyond the bench, and how global health work changed the way she thinks about laboratory infrastructure and clinical-trial design.The conversation then turns practical. Joleen defines patient-centric sampling, describes the Mitra dried blood collection device, and discusses a first-in-human RSV monoclonal antibody study in which paired dried-blood and serum samples led to aligned PK conclusions. She and Chad examine regulatory acceptance, remote collection, pediatric sampling, local laboratory capacity in African countries, scientific inclusion, career choices, AI, mass-spectrometry sensitivity, and whether long-standing sample-volume and stability expectations still serve patients.SponsorsTruTechnologies provides live clinical trial execution and oversight through point-of-care data capture. Learn more: https://trutechnologies.ai/Leucentra provides specialized IT consulting and services for life sciences and healthcare. Learn more: https://leucentra.com/In this episode, you will hear• How a personal connection to cystic fibrosis shaped Joleen's patient-first career• Why bioanalysis connects analytical rigor to decisions about drug safety, exposure, and patient benefit• What patient-centric sampling means beyond simply collecting less blood• How dried blood microsampling can support PK, immunogenicity, and viral-neutralization assessments• What Joleen's team learned by comparing dried blood with serum in a first-in-human study• Why smaller samples and remote collection can reduce burdens on patients, caregivers, sites, and enrollment• Why sustainable global health research depends on locally led scientific and laboratory capacity• How legacy automation can slow innovation and create opportunities for newer laboratory networks• Why inclusion and access expand both the scientific workforce and the quality of science• How personal values can guide career decisions more effectively than a rigid five-year plan• Why advances in mass spectrometry should prompt a fresh look at sample volumes and stability expectationsGuest and hostDr. Joleen White is a Senior Bioanalytical Consultant at BioData Solutions with more than 20 years of experience across regulated bioanalysis, ligand-binding assays, immunogenicity, cell-based assays, neutralizing-antibody assays, and data science.Connect with Joleen: https://www.linkedin.com/in/joleenwhite/BioData Solutions: https://www.bdatasolutions.com/Dr. Chad Briscoe is the co-host of BioTalk Unzipped and conducts this onsite conversation from AAPS NBC.Connect with Chad: https://www.linkedin.com/in/chadbriscoe/Resources mentionedOpen-access RSM01 dried blood microsampling study:https://pubmed.ncbi.nlm.nih.gov/39696004/Patient Centric Sampling Interest Group:https://www.pcsig.org/Follow BioTalk UnzippedWebsite and all episodes: https://www.biotalkunzipped.com/YouTube: https://www.youtube.com/@BioTalkUnzippedBioTalk Unzipped unzips, unlocks, and uncovers the real stories behind medical progress.
    Mostra di più Mostra meno
    48 min
  • Why Gene Therapy Is Still So Hard to Manufacture at Scale | Phillip Ramsey

    Why Gene Therapy Is Still So Hard to Manufacture at Scale | Phillip Ramsey
    Aug 8 2026
    Why is gene therapy still so difficult to manufacture at scale after decades of progress?Phillip Ramsey, Chief Technical Officer at Sangamo Therapeutics, joins BioTalk Unzipped for a candid conversation about one of the central challenges facing advanced therapies: turning extraordinary science into reproducible, scalable medicines.Thank You to Our SponsorsLeucentra - https://leucentra.com/Inspired by Science. Empowered by IT. Leucentra provides specialized IT consulting and services for life sciences and healthcare, helping organizations use technology more effectively to support innovation.TruTechnologies - https://trutechnologies.ai/Clinical Trial Execution, Live. TruTechnologies provides live clinical trial execution technology that gives sponsors greater visibility into protocol activities, samples, and study data as they happen.About This EpisodeRecorded onsite at the AAPS National Biotechnology Conference in Boston, Phillip explains why gene therapy manufacturing has not yet reached the maturity of monoclonal antibody production.As technologies have evolved across retroviral vectors, lentiviral vectors, adenovirus, AAV, lipid nanoparticles, and other advanced modalities, development teams have repeatedly been required to rethink fundamental manufacturing and analytical questions.Phillip discusses why analytics are critical, why experience across multiple manufacturing lots and products matters, and why there simply is no shortcut to developing the scientific knowledge necessary to manufacture advanced therapies reliably.He also reflects on the uncertainty of biotechnology.Early in his career, Phillip was walking down a hallway when his CFO asked if he had cashed his paycheck.When he said no, she told him not to.It's a remarkable story that captures something rarely discussed about biotechnology: behind transformative science are people willing to operate through considerable uncertainty while trying to build something that has never existed before.Gregory and Phillip Discuss• Viral vector manufacturing and scale-up• Why analytics are essential to gene therapy development• AAV manufacturing challenges• Lentiviral vectors and other evolving delivery technologies• Lipid nanoparticles and changes in advanced therapy manufacturing• Why gene therapy cannot simply adopt the established monoclonal antibody manufacturing playbook• Building process knowledge across lots and products• Career resilience in biotechnology• Progress across AAV, CAR-T, and other advanced therapies• Gene therapy affordability• The importance of therapeutic durability• Outcomes-based payment models for advanced therapiesPhillip's message for scientists and industry leaders is straightforward: don't assume the manufacturing problem has already been solved simply because a technology has existed for decades.The field is still evolving, and some knowledge cannot be shortcut.About Phillip RamseyPhillip Ramsey is Chief Technical Officer at Sangamo Therapeutics and brings more than 35 years of experience across biotechnology and pharmaceutical manufacturing, technical development, operations, quality, and advanced therapies.Connect with Phillip Ramsey:https://www.linkedin.com/in/phillip-ramsey-a2074711/Sangamo Therapeutics:https://www.sangamo.com/Connect With BioTalk UnzippedGregory Austin on LinkedIn:https://www.linkedin.com/in/gregoryaustin1/Dr. Chad Briscoe on LinkedIn:https://www.linkedin.com/in/chadbriscoe/BioTalk Unzipped:https://www.biotalkunzipped.com/BioTalk Unzipped unzips, unlocks, and uncovers the stories behind medical progress through conversations with scientists, executives, entrepreneurs, and innovators advancing biotechnology, pharmaceuticals, and medical technology.Recorded onsite at the AAPS National Biotechnology Conference in Boston.Special thanks to AAPS and Rebecca Stauffer for supporting the BioTalk Unzipped interview series.
    Mostra di più Mostra meno
    11 min
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione